咨询电话：15012456311
咨询电话：15012456311匹伐他汀背景及作用机理：
冠心病是威胁人类健康和生命的常见病和多发病，以低密度脂蛋白(LDL)升高为特征的高胆固醇血症则是诱发冠心病的主要危险因子之一。常用的降血脂药如烟酸类、树脂类或贝特类等疗效都难尽人意，降脂作用的是被称为他汀类(statins)的药物。他汀类药物共同的作用机制是都属于3—羟—3—甲基—戊二酰辅酶A(HMG—CoA)还原酶抑制剂，目前在世界广泛应用的主要有6种：洛伐他汀(lovastatin)，普伐他汀(pravastatin)，辛伐他汀(simvastatin)，西立伐他汀(cerivastatin)，氟伐他汀(fluvastatin)和阿托伐他汀(atorvastatin)。而近期由Kowa公司开发的新型他汀类药物匹他伐他汀钙，因其良好的降胆固醇作用而被称为“超级他汀类药物”(Superstatin)。
深圳远扬化学技术有限公司可提供匹伐他汀申报所用全套杂质， 随货附CoA证书，HNMR，MS，HPLC图谱，纯度符合申报要求，匹伐他汀杂质为我司优势杂质，长期备有库存，发货快。如需匹伐他汀钙杂质相关详细信息，欢迎我司业务人员（何：phastandards Q.Q:781007885）获取~
除自主品牌杂质对照品外，我司还代理英国NIBSC标准品，美国剑桥CIL同位素标准品，美国NIST标准物质，欧洲标准局IRMM标准物质，加拿大TRC标准品，TLC标准品，MOLCAN标准品，NRC标准品等，欢迎洽谈。
附：匹伐他汀申报用全套杂质列表：
| Pitavastatin | (+)-Monocalcium bis |
| Pitavastatin Impurity 1 | (3R,6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-3-hydroxy-5-oxo-6-heptenoate |
| Pitavastatin Impurity 2 | (3S,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt |
| Pitavastatin Impurity 3 | (4R,6S,E)-6-[2-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl] vinyl] tetrahydro-4-hydroxypyran-2-one |
| Pitavastatin Impurity 4 | 7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic Acid |
| Pitavastatin Impurity 5 | (3R,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt |
| Pitavastatin Impurity 6 | (3S,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt |
| Pitavastatin Impurity 7 | (3R,5S,6E)-7-[2-Cyclopropyl-4-phenyl-quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt |
| Pitavastatin Impurity 8 | [[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]methyl]triphenyl-phosphonium Bromide |
| Pitavastatin Impurity 9 | (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-2,2-dimethyl-1,3-dioxane-6-heptenoic acid t-butyl ester |
| Pitavastatin Impurity 10 | (3R,5S,E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxy-N-(1-phenylethyl)hept-6-enamide |
| Pitavastatin Impurity 11 | Sodium (5S, 6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate |
| Pitavastatin Impurity 12 | Ethyl (3R, 6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3- quinolinyl]-3-hydroxy-5-oxo-6-heptenoate |
| Pitavastatin Impurity 13 | Ethyl (5S, 6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate |
| Pitavastatin Impurity 14 | (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid methyl ester |
| Pitavastatin Impurity 15 | (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester |
| Pitavastatin Impurity 16 | (3R,5S)-5-(6-Cyclopropyl-10-fluoro-7,8-dihydrobenzo[k]phenanthridin-8-yl)-3,5-dihydroxypentanoic acid sodium salt |
| Pitavastatin Impurity 17 | 2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinemethanol |
| Pitavastatin Impurity 18 | (3R,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester |
| Pitavastatin Impurity 19 | (3S,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester |
| Pitavastatin Impurity 20 | (3S,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester |
| Pitavastatin Impurity 21 | (3R,5S,6E)-7-(2-Cyclopropyl-4-phenyl-3-quinolinyl)-3,5-dihydroxy-6-heptenoic Acid tert-Butyl Ester |
| Pitavastatin Impurity 22 | 2-((4R,6S)-6-((E)-2-(2-Cyclopropyl-4-phenylquinolin-3-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetic Acid tert-Butyl Ester |
